AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37085812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal pouch anal anastomosis
Number of subjects: 0
Study 37085812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileorectal anastomosis
Number of subjects: 0
Study 37085812 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients declining reconstruction or not eligible for both methods)
Number of subjects: 0
Study 37085833 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezo-electric instruments
Number of subjects: 22
Study 37085833 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling burs
Number of subjects: 22
Study 37085849 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic score (TScore)
Number of subjects: 176
Study 37085862 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing (ES) diagnostic test for ID
Number of subjects: 0
Study 37085862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with price decrease of 20% for the capture kit and 50% for the sequencing support kit
Number of subjects: 0
Study 37085877 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 ratings
Number of subjects: 0
Study 37085877 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIS-2 wheels
Number of subjects: 0
Study 37085877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 0
Study 37085877 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up/data collection domain
Number of subjects: 0
Study 37085877 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPICE qualitative approach
Number of subjects: 0
Study 37085880 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic bladder therapy (tolterodine 2 mg ER)
Number of subjects: 270
Study 37085880 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-3 adrenergic agonist bladder therapy (mirabegron 25 mg ER)
Number of subjects: 270
Study 37085880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 37085899 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals delivered daily to participants' homes by a volunteer or paid driver who socializes with the client
Number of subjects: 243
Study 37085899 — intervention group
Group type: COMPARATOR
Intervention: Frozen meals that are mailed to participants' homes
Number of subjects: 243
Study 37085935 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal levels of cardiorespiratory fitness (CRF)
Number of subjects: 60
Study 37085935 — intervention group
Group type: COMPARATOR
Intervention: Low levels of cardiorespiratory fitness (CRF)
Number of subjects: 60
Study 37085935 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, fatmass, and physical activity level
Number of subjects: 60
Study 37086054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI)
Number of subjects: 58
Study 37086055 — intervention group
Group type: COMPARATOR
Intervention: Bed provision and sleep education (BfK program)
Number of subjects: 27
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without antihypertensives
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without a patent foramen ovale (PFO)
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients after excluding those in the first tertile of delay between stroke and ABPM
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dipping patterns of BP in participants with a PFO
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dipping patterns of BP in participants without hypertension
Number of subjects: 238
Study 37086083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal non-dipping patterns of blood pressure
Number of subjects: 238
Study 37086209 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with bronchiectasis
Number of subjects: 24
Study 37086209 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 37086257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 706
Study 37086257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 706
Study 37086257 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 706
Study 37086340 — intervention group
Group type: COMPARATOR
Intervention: DMT fumarate (SPL026) administered via a two-phase intravenous (IV) infusion, escalating doses of 9-21.5 mg (DMT freebase) over a 10-min infusion.
Number of subjects: 24
Study 37086362 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 61
Study 37086362 — intervention group
Group type: COMPARATOR
Intervention: Standard care control arm
Number of subjects: 61
Study 37086568 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl aspartate (NAA) measured by MRS
Number of subjects: 27
Study 37086568 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine/glutamate/GABA measured by MRS
Number of subjects: 27
Study 37086595 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN+PEMBRO (Lenvatinib 20 mg/day + Pembrolizumab 200 mg Q3W)
Number of subjects: 827
Study 37086595 — intervention group
Group type: COMPARATOR
Intervention: TPC (Treatment of Physician's Choice, doxorubicin 60 mg/m2)
Number of subjects: 827
Study 37086595 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN+PEMBRO
Number of subjects: 827
Study 37086595 — intervention group
Group type: COMPARATOR
Intervention: TPC
Number of subjects: 827
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (energy and protein intakes)
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace element monitoring
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 35
Study 37086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 35
Study 37086618 — intervention group
Group type: EXPERIMENTAL
Intervention: EVEN protein intake (30% at each main meal)
Number of subjects: 24
Study 37086618 — intervention group
Group type: COMPARATOR
Intervention: SKEWED protein intake (15% at breakfast and lunch, 60% at dinner)
Number of subjects: 24
Study 37086745 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg intravenously once every 3 weeks)
Number of subjects: 608
Study 37086745 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (capecitabine 1250 mg/m2)
Number of subjects: 608
Study 37086745 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 608
Study 37086745 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 608
Study 37086854 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) in clean-contaminated cases
Number of subjects: 335
Study 37086854 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) in contaminated-dirty cases
Number of subjects: 335
Study 37086854 — intervention group
Group type: COMPARATOR
Intervention: Clean-contaminated cases
Number of subjects: 335
Study 37086854 — intervention group
Group type: COMPARATOR
Intervention: Contaminated-dirty cases
Number of subjects: 335
Study 37086854 — intervention group
Group type: COMPARATOR
Intervention: Inpatient costs after clean-contaminated surgery
Number of subjects: 335
Study 37086854 — intervention group
Group type: COMPARATOR
Intervention: Inpatient costs after contaminated-dirty surgery
Number of subjects: 335
Study 37086916 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention including a Fitbit linked with clinic's patient portal and EHR with weekly feedback
Number of subjects: 323
Study 37086916 — intervention group
Group type: EXPERIMENTAL
Intervention: Online gym (step-up condition for non-responders)
Number of subjects: 323
Study 37086916 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching calls (step-up condition for non-responders)
Number of subjects: 323
Study 37087308 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual analysis by core laboratory (CL)
Number of subjects: 0
Study 37087308 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) algorithm
Number of subjects: 0
Study 37087332 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on perioperative neuromuscular block management
Number of subjects: 2314
Study 37087399 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib modifications (dose reduction or treatment interruption)
Number of subjects: 219
Study 37087399 — intervention group
Group type: COMPARATOR
Intervention: No modifications
Number of subjects: 219
Study 37087399 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib modifications
Number of subjects: 219
Study 37087424 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 61
Study 37087424 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MCT)
Number of subjects: 61
Study 37087437 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Preventive Intervention
Number of subjects: 286
Study 37087437 — intervention group
Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 286
Study 37087459 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 752
Study 37087459 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Abatacept + Methotrexate
Number of subjects: 752
Study 37087459 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept Monotherapy
Number of subjects: 752
Study 37087459 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalated/Withdraw Abatacept
Number of subjects: 752
Study 37087459 — intervention group
Group type: COMPARATOR
Intervention: Abatacept Placebo + Methotrexate
Number of subjects: 752
Study 37087470 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 9
Study 37087709 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-viewing phase in MDD patients
Number of subjects: 0
Study 37087709 — intervention group
Group type: COMPARATOR
Intervention: Free-viewing phase in healthy controls (HC)
Number of subjects: 0
Study 37087709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fMRI and eye-tracking measurements
Number of subjects: 0
Study 37087950 — intervention group
Group type: EXPERIMENTAL
Intervention: ide-cel treatment
Number of subjects: 45
Study 37088093 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 288
Study 37088093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 288
Study 37088093 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification plus best medical care
Number of subjects: 288
Study 37088093 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (per protocol analysis)
Number of subjects: 288
Study 37088093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (per protocol analysis)
Number of subjects: 288
Study 37088093 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification plus best medical care (per protocol analysis)
Number of subjects: 288
Study 37088096 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI BA.1 boost (Ad/P)
Number of subjects: 187
Study 37088096 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 OMI BA.1 boost (mRNA/P)
Number of subjects: 187
Study 37088096 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 boost (Ad/M)
Number of subjects: 187
Study 37088096 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 boost (mRNA/M)
Number of subjects: 187
Study 37088096 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Ad/P and mRNA/P
Number of subjects: 187
Study 37088096 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Ad/M and mRNA/M
Number of subjects: 187
Study 37088107 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 11
Study 37088107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 11
Study 37088129 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-AIR program (evidence-based school- and/or home-based asthma management interventions)
Number of subjects: 433
Study 37088129 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions (child and caregiver education programs, school staff trainings)
Number of subjects: 433
Study 37088129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based interventions (individualized asthma education, home-environmental assessments, strategies and supplies for trigger remediation)
Number of subjects: 433
Study 37088275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (Dexcom G6 Pro) for 10 days starting at the 50-g glucose challenge test.
Number of subjects: 136
Study 37088280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of APOA-1
Number of subjects: 310
Study 37088280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-unit decrease of APOA-1
Number of subjects: 310
Study 37088310 — intervention group
Group type: EXPERIMENTAL
Intervention: High target mean arterial pressure (H-MAP) 80-85 mmHg
Number of subjects: 150
Study 37088311 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF test
Number of subjects: 3378
Study 37088311 — intervention group
Group type: COMPARATOR
Intervention: FIB-4
Number of subjects: 3378
Study 37088311 — intervention group
Group type: COMPARATOR
Intervention: NFS
Number of subjects: 3378
Study 37088311 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 followed by ELF
Number of subjects: 3378
Study 37088312 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX for 12 weeks (Group A)
Number of subjects: 315
Study 37088312 — intervention group
Group type: COMPARATOR
Intervention: SOF/VEL/VOX + weight-based ribavirin for 12 weeks (Group B)
Number of subjects: 315
Study 37088312 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX (Group A)
Number of subjects: 315
Study 37088312 — intervention group
Group type: COMPARATOR
Intervention: SOF/VEL/VOX + ribavirin (Group B)
Number of subjects: 315
Study 37088337 — intervention group
Group type: EXPERIMENTAL
Intervention: HT MCS (Mechanical Circulatory Support)
Number of subjects: 276
Study 37088337 — intervention group
Group type: COMPARATOR
Intervention: HT non-MCS (Awaiting transplant without MCS)
Number of subjects: 276
Study 37088337 — intervention group
Group type: COMPARATOR
Intervention: Prior to long-term MCS
Number of subjects: 276
Study 37088376 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 37088401 — intervention group
Group type: EXPERIMENTAL
Intervention: Double umbilical cord blood transplantation (dUCBT)
Number of subjects: 0
Study 37088401 — intervention group
Group type: COMPARATOR
Intervention: HLA-haploidentical bone marrow transplantation (haplo-BMT)
Number of subjects: 0
Study 37088447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride)
Number of subjects: 90
Study 37088447 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic displacement (PD) with tPA and VEGF inhibitor
Number of subjects: 90
Study 37088447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Surgery and PD)
Number of subjects: 90
Study 37088457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg)
Number of subjects: 197
Study 37088457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 37088458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg) injected subcutaneously once weekly for 48 weeks
Number of subjects: 155
Study 37088458 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected subcutaneously once weekly for 48 weeks
Number of subjects: 155
Study 37088458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (10, 20, or 40 mg)
Number of subjects: 155
Study 37088458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin (20 or 40 mg)
Number of subjects: 155
Study 37088458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegbelfermin
Number of subjects: 155
Study 37088458 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg pegbelfermin
Number of subjects: 155
Study 37088866 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorex penile traction therapy (RxPTT)
Number of subjects: 82
Study 37088866 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Tx)
Number of subjects: 82
Study 37088866 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Tx (Group 2)
Number of subjects: 82
Study 37088866 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to no treatment after initial treatment (Group 3)
Number of subjects: 82
Study 37088964 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB and MenACWY vaccines
Number of subjects: 55
Study 37089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic and topical medications
Number of subjects: 0
Study 37089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation study
Number of subjects: 0
Study 37089721 — intervention group
Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 0
Study 37089722 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended group body psychotherapy (BPT)
Number of subjects: 40
Study 37089722 — intervention group
Group type: COMPARATOR
Intervention: Waiting-period comparator
Number of subjects: 40
Study 37089863 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma
Number of subjects: 0
Study 37089863 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic immune suppression
Number of subjects: 0
Study 37089863 — intervention group
Group type: EXPERIMENTAL
Intervention: LRG1 as a potential target and biomarker
Number of subjects: 0
Study 37090002 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital CBTi
Number of subjects: 77
Study 37090015 — intervention group
Group type: EXPERIMENTAL
Intervention: MISSION-Vet intervention
Number of subjects: 42
Study 37090089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapies (LLTs)
Number of subjects: 9044
Study 37090123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Speckle Contrast Imaging (LSCI)
Number of subjects: 4
Study 37090129 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) population in Japan
Number of subjects: 800
Study 37090438 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib plus nivolumab
Number of subjects: 70
Study 37090440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg)
Number of subjects: 3780
Study 37090440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780
Study 37090440 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy (rosuvastatin 20 mg)
Number of subjects: 3780
Study 37090566 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE-CITE-Gait intervention
Number of subjects: 15
Study 37090860 — intervention group
Group type: EXPERIMENTAL
Intervention: NEUROMARK® system (radiofrequency ablation to the posterior nasal nerves)
Number of subjects: 36
Study 37090974 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT-A)
Number of subjects: 86
Study 37091033 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 0
Study 37091033 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 0
Study 37091033 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 37091450 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) based parameters: Mean Flow Velocity (MFV)
Number of subjects: 0
Study 37091450 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) based parameters: Pulsatility Index (PI)
Number of subjects: 0
Study 37091505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of flap perfusion using ICG-NIR-FA
Number of subjects: 280
Study 37091505 — intervention group
Group type: COMPARATOR
Intervention: Regular clinical parameters only (Control)
Number of subjects: 280
Study 37091508 — intervention group
Group type: EXPERIMENTAL
Intervention: Online opioid overdose education and remote distribution of naloxone kits
Number of subjects: 0
Study 37091508 — intervention group
Group type: COMPARATOR
Intervention: Information on where to obtain a naloxone kit
Number of subjects: 0
Study 37091509 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy group prenatal care model
Number of subjects: 0
Study 37091509 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Number of subjects: 0
Study 37091507 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based financial incentive intervention for cigarette smoking cessation
Number of subjects: 0
Study 37091507 — intervention group
Group type: COMPARATOR
Intervention: No-incentives control condition
Number of subjects: 0
Study 37091538 — intervention group
Group type: EXPERIMENTAL
Intervention: TFT-TFS program implementation
Number of subjects: 219
Study 37091549 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test use
Number of subjects: 48
Study 37091549 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to home pregnancy test use
Number of subjects: 48
Study 37091549 — intervention group
Group type: EXPERIMENTAL
Intervention: Community knowledge improvement
Number of subjects: 48
Study 37091963 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 60